Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:01:12 ON 12 DEC 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:01:21 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0
DICTIONARY FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591757a.str





chain nodes :
12 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
7-12 12-13 16-19 17-20 18-21
ring bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 7-12 8-9 12-13 13-14 13-18 14-15
15-16 16-17 16-19 17-18 17-20 18-21
isolated ring systems :
containing 1 : 13 :

G1:C,N

G2:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10591757a.str





chain nodes :
12 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
7-12 12-13 16-19 17-20 18-21
ring bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 7-12 8-9 12-13 13-14 13-18 14-15
15-16 16-17 16-19 17-18 17-20 18-21
isolated ring systems :
containing 1 : 13 :

G1:C,N

G2:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS

L2 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 13:02:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 132 TO 668
PROJECTED ANSWERS: 4 TO 200

L3 4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:02:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 376 TO ITERATE

100.0% PROCESSED 376 ITERATIONS 88 ANSWERS
SEARCH TIME: 00.00.01

L4 88 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.55 172.76

FILE 'CAPLUS' ENTERED AT 13:02:15 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l4 full
L5 1 L4

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1004761 CAPLUS
DOCUMENT NUMBER: 143:306497
TITLE: Preparation of nitrogenous fused-ring glycoside derivatives as inhibitors of human sodium-dependent glucose transporter (SGLT)
INVENTOR(S): Fushimi, Nobuhiko; Teranishi, Hirotaka; Shimizu, Kazuo; Yonekubo, Shigeru; Ito, Fumiaki; Isaji, Masayuki
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085267	A1	20050915	WO 2005-JP4145	20050303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005219776	A1	20050915	AU 2005-219776	20050303
CA 2557766	A1	20050915	CA 2005-2557766	20050303
EP 1724278	A1	20061122	EP 2005-720416	20050303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1950389	A	20070418	CN 2005-80014287	20050303
BR 2005008243	A	20070724	BR 2005-8243	20050303
MX 2006PA09899	A	20061211	MX 2006-PA9899	20060831
US 2007191289	A1	20070816	US 2006-591757	20060901
IN 2006DN05080	A	20070622	IN 2006-DN5080	20060904

PRIORITY APPLN. INFO.: JP 2004-61426 A 20040304
WO 2005-JP4145 W 20050303

OTHER SOURCE(S): MARPAT 143:306497
GI



L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Nitrogenous fused-ring glycoside derivs. such as 1H-pyrazolo[3,4-b]pyridin-3-yl β-D-glucopyranosides and 1H-indazol-3-yl β-D-glucopyranosides (I) [R1 = H, C1-6 alkyl, halo-C1-6 alkyl, (di)hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C2-7 alkoxycarbonyl-C1-6 alkyl, CO2H-C1-6 alkyl, C2-6 alkenyl, each (un)substituted C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C8-10 aryl, or C6-10 aryl-C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl; R3, R4 = H, HO, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C2-6 alkenylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C2-6 alkenyl, hydroxy-C1-6 alkoxy, etc.; Y = CH, N; Q = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C1-6 alkylene-O-, C1-6 alkylene-S, O-C1-6 alkylene, S-C1-6 alkylene, each N-(un)substituted CONH, NHCO, C1-6 alkylene-CONH, CONH-C1-6 alkylene; the ring A = C6-10 aryl or heteroaryl; G = Q1, Q2; E1 = H, F, OH; E2 = H, F, Me, HOCH2] are prepared These compds. exert human SGLT1 or SGLT2 inhibiting activity and are useful as suppressants of high serum glucose after eating or as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hyperglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout. Thus, a mixture of 75 mg 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole, 33 mg styrene, 0.073 mL Et3N, 2 mg Pd(OAc)2, 6 mg tris(2-methylphenyl)phosphine, and 2 mL MeCN was refluxed overnight under Ar to give, after silica gel chromatog., 50 mg 4-[(E)-2-phenylethenyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole which (50 mg) was dissolved in 4 mL THF and hydrogenated in the presence of 10% Pd-C under H atmospheric for 5 h, filtered, and concentrated to give 50 mg 4-(2-phenylethyl)-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (II). II was stirred with NaOMe in MeOH at 50° overnight and treated with 0.04 mL AcOH to give, after silica gel chromatog., 21 mg 3-(β-D-glucopyranosyloxy)-4-(2-phenylethyl)-1H-indazole (III). III and 3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine showed IC50 of 68 and 90 nM, resp., for inhibiting the uptake of 14C-labeled Me α-D-glucopyranoside CS2-5E cells.

IT 864844-68-8P 864846-28-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864844-68-8 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864846-28-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



IT 864844-07-5P 864844-08-6P 864844-09-7P
864844-14-4P 864844-15-5P 864844-16-6P
864844-17-7P 864844-18-8P 864844-19-9P
864844-20-2P 864844-22-4P 864844-23-5P
864844-25-7P 864844-27-9P 864844-28-0P
864844-29-1P 864844-30-4P 864844-32-6P
864844-34-8P 864844-36-0P 864844-37-1P
864844-38-2P 864844-39-3P 864844-41-7P
864844-42-8P 864844-43-9P 864844-44-0P
864844-45-1P 864844-46-2P 864844-47-3P
864844-48-4P 864844-49-5P 864844-50-8P
864844-51-9P 864844-52-0P 864844-53-1P
864844-54-2P 864844-55-3P 864844-56-4P
864844-58-6P 864844-62-2P 864844-63-3P
864844-69-9P 864844-70-2P 864844-71-3P
864844-72-4P 864844-73-5P 864844-74-6P
864844-75-7P 864844-76-8P 864844-77-9P
864844-78-0P 864844-79-1P 864844-80-4P
864844-81-5P 864844-82-6P 864844-83-7P
864844-84-8P 864844-85-9P 864844-86-0P
864844-87-1P 864844-88-2P 864844-89-3P
864844-90-6P 864844-95-1P 864844-96-2P
864844-97-3P 864844-98-4P 864844-99-5P
864845-00-1P 864845-01-2P 864845-02-3P
864845-04-5P 864845-05-6P 864845-06-7P
864845-07-8P 864845-08-9P 864845-09-0P
864845-10-3P 864845-12-5P 864845-13-6P
864845-14-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864844-07-5 CAPLUS
CN β-D-Glucopyranoside, 4-(2-phenylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-08-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxy-3-methylphenyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-09-7 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-pyridinyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-14-4 CAPLUS
CN β-D-Glucopyranoside, 4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-15-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-16-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetic acid, 3-(β-D-glucopyranosyloxy)-4-[2-[4-(phenylmethoxy)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-17-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-18-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-N-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-19-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-20-2 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-22-4 CAPLUS
CN Propanamide, 2-[[3-[4-[2-[3-(β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridin-4-yl]ethyl]phenoxy]propyl]amino]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-23-5 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 864844-25-7 CAPLUS
CN Benzenebutanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridin-4-yl]ethyl]-N-[(1S)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-27-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-28-0 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(2-methoxyethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-29-1 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-30-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-32-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-butanamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-34-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(3-hydroxypropyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-38-2 CAPLUS
CN β-D-Glucopyranoside, 1-[2-(dimethylamino)ethyl]-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-39-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-36-0 CAPLUS
CN β-D-Glucopyranoside, 1-(3-aminopropyl)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-37-1 CAPLUS
CN Acetamide, 2-amino-N-[3-[3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-1-yl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 864844-41-7 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-42-8 CAPLUS
CN β-D-Glucopyranoside, 1-ethyl-4-[2-(4-methoxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-43-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-44-0 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-45-1 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-46-2 CAPLUS
CN Glycine, N-[[3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridin-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-47-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-48-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(3-hydroxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-49-5 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-50-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(3-methoxyphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-51-9 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-[2-(4-methylphenyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-52-0 CAPLUS
CN β-D-Glucopyranoside, 1-(1-methylethyl)-4-[2-(3-methylphenyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-53-1 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxyphenyl)ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-54-2 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-hydroxyphenyl)ethynyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-55-3 CAPLUS
CN β-D-Glucopyranoside, 4-[(3-hydroxyphenyl)ethynyl]-1-(1-methylethyl)-1H-indazol-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-56-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-(4-hydroxy-3-methylphenyl)ethyl]-1-(1-methylethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-58-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-62-2 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-(3-hydroxypropoxy)phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-63-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-hydroxypropoxy)phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-71-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-72-4 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl



RN 864844-69-9 CAPLUS
CN Propanamide, 3-[[3-[4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]phenoxy]propyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-70-2 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 864844-73-5 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-74-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[[3-(dimethylamino)propyl]amino]propoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-75-7 CAPLUS
CN Propanamide, 2-[[3-[4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]phenoxy]propyl]amino]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-77-9 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-78-0 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-76-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.







RN 864844-79-1 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]ethoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-80-4 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-[2-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]ethoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-81-5 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[4-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-84-8 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[3-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-85-9 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-82-6 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[3-[2-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]ethoxy]phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-83-7 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)



RN 864844-86-0 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-[2-[3-[3-[(2-hydroxyethyl)amino]propoxy]phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-87-1 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-aminopropoxy)phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-88-2 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(2-aminoethoxy)phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-89-3 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-aminopropoxy)phenyl]ethyl]-1-(2-hydroxyethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

RN 864844-95-1 CAPLUS
CN Benzenebutanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-96-2 CAPLUS
CN Benzenepentanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-90-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(β-D-glucopyranosyloxy)-4-[2-[4-[3-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.





RN 864844-97-3 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864844-98-4 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864844-99-5 CAPLUS
CN Benzenepentanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-00-1 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864845-04-5 CAPLUS
CN Benzenepropanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-05-6 CAPLUS
CN Benzenepropanamide, 4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (CA INDEX NAME)

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864845-01-2 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-02-3 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 864845-06-7 CAPLUS
CN Benzenepropanamide, N-[1,1-dimethyl-2-[4-(1-methylethyl)-1-piperazinyl]-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-07-8 CAPLUS
CN Benzenepropanamide, N-[1,1-dimethyl-2-[4-(2-methylpropyl)-1-piperazinyl]-2-

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-08-9 CAPLUS
CN Benzenebutanamide, N-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-09-0 CAPLUS

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzenebutanamide, N-(1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-13-6 CAPLUS
CN 1H-Indazole-1-acetamide, 4-[2-[4-[4-[[1,1-dimethyl-2-oxo-2-(1-piperazinyl]ethyl]amino]-4-oxobutyl]phenyl]ethyl]-3-(β-D-glucopyranosyloxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-14-7 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzenebutanamide, N-[2-(4-ethyl-1-piperazinyl)-1,1-dimethyl-2-oxoethyl]-4-[2-[3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-1H-indazol-4-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-10-3 CAPLUS
CN 1H-Indazole-1-acetamide, 4-[2-[4-(3-aminopropoxy)phenyl]ethyl]-3-(β-D-glucopyranosyloxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-12-5 CAPLUS

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 864845-32-9P 864845-35-2P 864845-66-9P
864845-67-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of
human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)
RN 864845-32-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-1-carboxamide, 3-(β-D-glucopyranosyloxy)-4-[2-[4-(phenylmethoxy]phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-35-2 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(phenylmethoxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-66-9 CAPLUS
CN β-D-Glucopyranoside, 4-[2-[4-(3-azidopropoxy)phenyl]ethyl]-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-67-0 CAPLUS
CN 1H-Indazole-1-acetamide, 4-[2-[4-(3-azidopropoxy)phenyl]ethyl]-3-(β-D-glucopyranosyloxy)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 13:01:12 ON 12 DEC 2007)

     FILE 'REGISTRY' ENTERED AT 13:01:21 ON 12 DEC 2007
L1                STRUCTURE UPLOADED
L2                STRUCTURE UPLOADED
L3             4 S L1
L4            88 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 13:02:15 ON 12 DEC 2007
L5             1 S L4 FULL

=> log
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       6.21     178.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.78      -0.78

STN INTERNATIONAL LOGOFF AT 13:03:17 ON 12 DEC 2007
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:54:46 ON 12 DEC 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:54:57 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0
DICTIONARY FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591757.str





chain nodes :
12 19 20 21 22 24
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
chain bonds :
6-22 7-12 12-13 16-19 17-20 18-21 22-24
ring bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18
exact/norm bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 6-22 7-8 7-12 8-9 12-13 13-14 13-18
14-15 15-16 16-17 16-19 17-18 17-20 18-21 22-24
isolated ring systems :
containing 1 : 13 :

G1:C,N

G2:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS
22:CLASS 24:Atom

Generic attributes :
24:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:56:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:56:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 190 TO ITERATE

100.0% PROCESSED 190 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.00	173.21

FILE 'CAPLUS' ENTERED AT 12:56:27 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1004761 CAPLUS
DOCUMENT NUMBER: 143:306497
TITLE: Preparation of nitrogenous fused-ring glycoside derivatives as inhibitors of human sodium-dependent glucose transporter (SGLT)
INVENTOR(S): Fushimi, Nobuhiko; Teranishi, Hirotaka; Shimizu, Kazuo; Yonekubo, Shigeru; Ito, Fumiaki; Isaji, Masayuki
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085267	A1	20050915	WO 2005-JP4145	20050303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005219776	A1	20050915	AU 2005-219776	20050303
CA 2557766	A1	20050915	CA 2005-2557766	20050303
EP 1724278	A1	20061122	EP 2005-720416	20050303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1950389	A	20070418	CN 2005-80014287	20050303
BR 2005008243	A	20070724	BR 2005-8243	20050303
MX 2006PA09899	A	20061211	MX 2006-PA9899	20060831
US 2007191289	A1	20070816	US 2006-591757	20060901
IN 2006DN05080	A	20070622	IN 2006-DN5080	20060904

PRIORITY APPLN. INFO.: JP 2004-61426 A 20040304
WO 2005-JP4145 W 20050303

OTHER SOURCE(S): MARPAT 143:306497
GI



L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Nitrogenous fused-ring glycoside derivs. such as 1H-pyrazolo[3,4-b]pyridin-3-yl β-D-glucopyranosides and 1H-indazol-3-yl β-D-glucopyranosides (I) [R1 = H, C1-6 alkyl, halo-C1-6 alkyl, (di)hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C2-7 alkoxycarbonyl-C1-6 alkyl, CO2H-C1-6 alkyl, C2-6 alkenyl, each (un)substituted C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C8-10 aryl, or C6-10 aryl-C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl; R3, R4 = H, HO, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C2-6 alkenylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C2-6 alkenyl, hydroxy-C1-6 alkoxy, etc.; Y = CH, N; Q = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C1-6 alkylene-O-, C1-6 alkylene-S, O-C1-6 alkylene, S-C1-6 alkylene, each N-(un)substituted CONH, NHCO, C1-6 alkylene-CONH, CONH-C1-6 alkylene; the ring A = C6-10 aryl or heteroaryl; G = Q1, Q2; E1 = H, F, OH; E2 = H, F, Me, HOCH2] are prepared These compds. exert human SGLT1 or SGLT2 inhibiting activity and are useful as suppressants of high serum glucose after eating or as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hyperglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout. Thus, a mixture of 75 mg 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole, 33 mg styrene, 0.073 mL Et3N, 2 mg Pd(OAc)2, 6 mg tris(2-methylphenyl)phosphine, and 2 mL MeCN was refluxed overnight under Ar to give, after silica gel chromatog., 50 mg 4-[(E)-2-phenylethenyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole which (50 mg) was dissolved in 4 mL THF and hydrogenated in the presence of 10% Pd-C under H atmospheric for 5 h, filtered, and concentrated to give 50 mg 4-(2-phenylethyl)-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (II). II was stirred with NaOMe in MeOH at 50° overnight and treated with 0.04 mL AcOH to give, after silica gel chromatog., 21 mg 3-(β-D-glucopyranosyloxy)-4-(2-phenylethyl)-1H-indazole (III). III and 3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine showed IC50 of 68 and 90 nM, resp., for inhibiting the uptake of 14C-labeled Me α-D-glucopyranoside CS2-5E cells.

IT 864845-14-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864845-14-7 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:54:46 ON 12 DEC 2007)

     FILE 'REGISTRY' ENTERED AT 12:54:57 ON 12 DEC 2007
L1                STRUCTURE UPLOADED
L2            0 S L1
L3            1 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 12:56:27 ON 12 DEC 2007
L4            1 S L3 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.74     178.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.78      -0.78

STN INTERNATIONAL LOGOFF AT 12:56:48 ON 12 DEC 2007
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:16:25 ON 12 DEC 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:17:14 ON 12 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0
DICTIONARY FILE UPDATES: 11 DEC 2007 HIGHEST RN 957570-32-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591757a.str





chain nodes :
12 13 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
6-13 7-12 13-15
ring bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 7-8 8-9
exact/norm bonds :
1-2 1-6 1-7 2-3 2-9 3-4 4-5 5-6 6-13 7-8 7-12 8-9 13-15
isolated ring systems :
containing 1 :

G1:C,N

G2:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
13:CLASS 15:Atom
Generic attributes :
15:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:17:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 319 TO ITERATE

100.0% PROCESSED 319 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5309 TO 7451
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:17:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6419 TO ITERATE

100.0% PROCESSED 6419 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

L3 17 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 13:17:40 ON 12 DEC 2007

FILE COVERS 1907 - 12 Dec 2007 VOL 147 ISS 25
FILE LAST UPDATED: 11 Dec 2007 (20071211/ED)

=> s l3 full
L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:593127 CAPLUS
DOCUMENT NUMBER: 147:31098
TITLE: Preparation of 3-amino-1-arylpropylindoles and aza-substituted indoles as biogenic monoamine reuptake inhibitors
INVENTOR(S): Iyer, Pravin; Lucas, Matthew C.; Schoenfeld, Ryan Craig; Villa, Marzia; Weikert, Robert James
PATENT ASSIGNEE(S): Roche Palo Alto LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 113pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007123527	A1	20070531	US 2006-605528	20061129
WO 2007062996	A1	20070607	WO 2006-EP68646	20061120

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-741266P P 20051130

OTHER SOURCE(S): MARPAT 147:31098
GI



I

AB The title compds. including 3-amino-1-arylpropylindoles and 3-amino-1-arylpropylindazoles [I; p = 1, 2; Y = N, CRe; Re = H, alkyl; Ar = each (un)substituted indolyl, indazolyl, pyrrolo[2,3-b]pyridyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, indolinyl, or 1,3-dihydroindol-2-onyl; R1 = each (un)substituted Ph, naphthyl, indolyl, indazolyl, pyridinyl, thienyl, furanyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuranyl, benzothiophenyl, benzoxazinyl, arylalkyl, or heteroarylalkyl, cycloalkyl, branched alkyl; R2 and R3 = H, alkyl, hydroxyalkyl, alkoxyalkyl, benzyl; or R2 and R3 together with the nitrogen to which they are attached may form an optionally substituted four to seven membered ring that optionally includes an addnl. heteroatom selected from N, O, and S; Ra = H, F, alkyl; Rb = H, alkyl, HO, alkoxy, F, hydroxyalkyl; Rc, Rd = H, alkyl; or Rc and Rd together form :O, :S, or :NRf; Rf = H, alkyl, HO, alkoxy; or one of R2 and R3 together with one of Ra and Rb or one of Rc and Rd together with the atoms to which they are attached may form a four to six membered ring that optionally includes an addnl. heteroatom selected from O, N and S] or pharmaceutically acceptable salts thereof are prepd. These compds. are effective as serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, dopamine reuptake inhibitors, and/or dual reuptake inhibitors of serotonin, norepinephrine and/or dopamine, or triple reuptake inhibitors of norepinephrine, serotonin, and dopamine and particularly useful for treating depression, anxiety, or a combination thereof mediated by serotonin or norepinephrine neurotransmission or a combination thereof. They may be also useful in the treatment of other diseases such as genitourinary diseases and pain assocd. with monoamine reuptake inhibitors. Thus, mesylation of 6-(3-Hydroxy-1-phenylpropyl)-1H-indole-3-carbonitrile by methanesulfonyl chloride in the presence of Et3N in THF/CH2Cl2 at 0° for 2.5 h followed by amination with 33% methylamine/ethanol in a sealed tube at 100° for 45 min gave 6-(3-methylamino-1-phenylpropyl)-1H-indole-3-carbonitrile (II). II showed IC50 of 9.4 μM against the binding of [3H]citalopram to human serotonin transporter (hSERT).

IT 938061-95-1P, 3-(3-Methoxy-1H-indazol-4-yl)-3-phenylacrylic acid ethyl ester 938061-96-2P, 3-(3-Methoxy-1H-indazol-4-yl)-N-methyl-3-phenylacrylamide 938061-97-3P, 3-(3-Methoxy-1H-indazol-4-yl)-N-methyl-3-phenylpropionamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 3-amino-1-arylpropylindoles and aza-substituted indoles as biogenic monoamine reuptake inhibitors for treating depression, anxiety, or pain)

RN 938061-95-1 CAPLUS
CN 2-Propenoic acid, 3-(3-methoxy-1H-indazol-4-yl)-3-phenyl-, ethyl ester (CA INDEX NAME)



RN 938061-96-2 CAPLUS
CN 2-Propenamide, 3-(3-methoxy-1H-indazol-4-yl)-N-methyl-3-phenyl- (CA INDEX NAME)



RN 938061-97-3 CAPLUS
CN 1H-Indazole-4-propanamide, 3-methoxy-N-methyl-β-phenyl- (CA INDEX NAME)



IT 938059-60-0P, N-[3-(3-Methoxy-1H-indazol-4-yl)-3-phenylpropyl]methylamine monotrifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-amino-1-arylpropylindoles and aza-substituted indoles as biogenic monoamine reuptake inhibitors for treating depression, anxiety, or pain)

RN 938059-60-0 CAPLUS
CN 1H-Indazole-4-propanamine, 3-methoxy-N-methyl-γ-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 938059-59-7
CMF C18 H21 N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:194015 CAPLUS
DOCUMENT NUMBER: 144:292768
TITLE: Preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors
INVENTOR(S): Stadtmueller, Heinz; Engelhardt, Harald; Steegmaier, Martin; Baum, Anke; Guertler, Ulrich; Schoop, Andreas; Quant, Jens; Solca, Flavio; Hauptmann, Rudolf; Reiser, Ulrich; Zahn, Stephan Karl; Herfurth, Lars
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: PCT Int. Appl., 272 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021544	A1	20060302	WO 2005-EP54089	20050818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006148800	A1	20060706	US 2005-206703	20050817
AU 2005276500	A1	20060302	AU 2005-276500	20050818
CA 2573371	A1	20060302	CA 2005-2573371	20050818
EP 1781640	A1	20070509	EP 2005-777896	20050818
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101044137	A	20070926	CN 2005-80035995	20050818
IN 2007DN00365	A	20070803	IN 2007-DN365	20070115
KR 2007048757	A	20070509	KR 2007-704974	20070228

PRIORITY APPLN. INFO.: EP 2004-19775 A 20040820
WO 2005-EP54089 W 20050818

OTHER SOURCE(S): MARPAT 144:292768
GI

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [W = N, CR2; X = O, S, NR1a; Y = CH, N; Z = H, halo, NO2, etc.; A = mono or bicyclic aryl ring (sic); R1, R1a = H, CH3; R2 = H, halo, OR4, etc.; Ra, Rb, Rc = H, halo, =O, etc.; R4 = H, alkyl, alkenyl, etc.; R3 = CON(R1)LQ2Q3R7, N(R1)COLQ2Q3R7, etc.; L = bond, alkyl, alkenyl, etc.; Q2, Q3 = bond, alkyl, alkenyl, etc.; R7 = H, alkyl, alkenyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of chloropyrimidine II and 7-amino-2,3-dihydroisoindol-1-one afforded diaminophenylpyrimidine III in 33% yield. Compds. I are claimed to be useful for the treatment of diseases characterized by excessive or anomalous cell proliferation.

IT 878143-73-8P 878143-74-9P 878152-65-9P 878152-67-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors)

RN 878143-73-8 CAPLUS
CN Benzamide, 4-[[4-[(2,3-dihydro-3-oxo-1H-indazol-4-yl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 878143-74-9 CAPLUS
CN Benzamide, 4-[[4-[(2,3-dihydro-1-methyl-3-oxo-1H-indazol-4-yl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)



RN 878152-65-9 CAPLUS
CN Benzamide, 4-[[4-[(1-ethyl-2,3-dihydro-3-oxo-1H-indazol-4-yl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-[trans-4-(4-morpholinyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

Et

RN 878152-67-1 CAPLUS
CN Benzamide, 4-[[4-[(2,3-dihydro-1-(2-hydroxyethyl)-3-oxo-1H-indazol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-[trans-4-(4-morpholinyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1004761 CAPLUS
DOCUMENT NUMBER: 143:306497
TITLE: Preparation of nitrogenous fused-ring glycoside derivatives as inhibitors of human sodium-dependent glucose transporter (SGLT)
INVENTOR(S): Fushimi, Nobuhiko; Teranishi, Hirotaka; Shimizu, Kazuo; Yonekubo, Shigeru; Ito, Fumiaki; Isaji, Masayuki
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085267	A1	20050915	WO 2005-JP4145	20050303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005219776	A1	20050915	AU 2005-219776	20050303
CA 2557766	A1	20050915	CA 2005-2557766	20050303
EP 1724278	A1	20061122	EP 2005-720416	20050303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1950389	A	20070418	CN 2005-80014287	20050303
BR 2005008243	A	20070724	BR 2005-8243	20050303
MX 2006PA09899	A	20061211	MX 2006-PA9899	20060831
US 2007191289	A1	20070816	US 2006-591757	20060901
IN 2006DN05080	A	20070622	IN 2006-DN5080	20060904

PRIORITY APPLN. INFO.: JP 2004-61426 A 20040304
WO 2005-JP4145 W 20050303

OTHER SOURCE(S): MARPAT 143:306497
GI



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Nitrogenous fused-ring glycoside derivs. such as 1H-pyrazolo[3,4-b]pyridin-3-yl β-D-glucopyranosides and 1H-indazol-3-yl β-D-glucopyranosides (I) [R1 = H, C1-6 alkyl, halo-C1-6 alkyl, (di)hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C2-7 alkoxycarbonyl-C1-6 alkyl, CO2H-C1-6 alkyl, C2-6 alkenyl, each (un)substituted C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C8-10 aryl, or C6-10 aryl-C1-6 alkyl, etc.; R2 = H, halo, C1-6 alkyl; R3, R4 = H, HO, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylthio, C2-6 alkenylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C2-6 alkenyl, hydroxy-C1-6 alkoxy, etc.; Y = CH, N; Q = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C1-6 alkylene-O-, C1-6 alkylene-S, O-C1-6 alkylene, S-C1-6 alkylene, each N-(un)substituted CONH, NHCO, C1-6 alkylene-CONH, CONH-C1-6 alkylene; the ring A = C6-10 aryl or heteroaryl; G = Q1, Q2; E1 = H, F, OH; E2 = H, F, Me, HOCH2] are prepared These compds. exert human SGLT1 or SGLT2 inhibiting activity and are useful as suppressants of high serum glucose after eating or as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hyperglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout. Thus, a mixture of 75 mg 4-bromo-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole, 33 mg styrene, 0.073 mL Et3N, 2 mg Pd(OAc)2, 6 mg tris(2-methylphenyl)phosphine, and 2 mL MeCN was refluxed overnight under Ar to give, after silica gel chromatog., 50 mg 4-[(E)-2-phenylethenyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole which (50 mg) was dissolved in 4 mL THF and hydrogenated in the presence of 10% Pd-C under H atmospheric for 5 h, filtered, and concentrated to give 50 mg 4-(2-phenylethyl)-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-indazole (II). II was stirred with NaOMe in MeOH at 50° overnight and treated with 0.04 mL AcOH to give, after silica gel chromatog., 21 mg 3-(β-D-glucopyranosyloxy)-4-(2-phenylethyl)-1H-indazole (III). III and 3-(β-D-glucopyranosyloxy)-1-(2-hydroxyethyl)-4-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine showed IC50 of 68 and 90 nM, resp., for inhibiting the uptake of 14C-labeled Me α-D-glucopyranoside CS2-5E cells.

IT 864845-14-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864845-14-7 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 864845-69-2P 864845-70-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrogenous fused-ring glycoside derivs. as inhibitors of human sodium-dependent glucose transporter (SGLT) for prevention or treatment of hyperglycemia)

RN 864845-69-2 CAPLUS
CN β-D-Glucopyranoside, 1-(2-(phenylmethoxy)ethyl)-4-(phenylmethyl)-1H-indazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



RN 864845-70-5 CAPLUS
CN β-D-Glucopyranoside, 1-(2-hydroxyethyl)-4-(phenylmethyl)-1H-indazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1154679 CAPLUS
DOCUMENT NUMBER: 142:93813
TITLE: A preparation of indazole and pyrazolopyridine derivatives, useful as JNK inhibitors
INVENTOR(S): Ford, Rhonan; Leroux, Frederic; Stocks, Michael; Swahn, Britt-Marie
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113303	A1	20041229	WO 2004-SE1015	20040623

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: SE 2003-1906 A 20030626

OTHER SOURCE(S): MARPAT 142:93813
GI



I II

AB The invention relates to a preparation of indazole and pyrazolopyridine derivs.
of formula I (wherein: X is N, CH, C-NO2, or C-CN, etc.; R1 is O-CH2-aryl,
NHC(O)-(H/alkyl), or NH2, etc.; R2 is H, O-aryl, or NH-aryl, etc.; R3 is H
or NH-Ar; Ar is benzene optionally substituted with one or more of alkyl, fluoroalkyl, hydroxyalkyl, etc.], useful as JNK inhibitors. For instance,
(benzylamino)pyrazolopyridine derivative II (R4 = 2,5-dimethoxybenzyl) was
prepared via phenoxylation of 2-chloro-4-methoxy-3-pyridinecarbonitrile, heterocyclization with hydrazine, and subsequent reductive N-benzylation

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
of the obtained aminopyrazolopyridine deriv. II (R4 = H) by 2,5-dimethoxybenzaldehyde. Typical Ki values of the invention compds. of formula I are in the range of about 0.001 to about 10000 nM.

IT 816454-64-5P, 3-[(2-Chlorobenzyl)oxy]-4-phenoxy-1H-indazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole and pyrazolopyridine derivs. useful as JNK inhibitors)

RN 816454-64-5 CAPLUS
CN 1H-Indazole, 3-[(2-chlorophenyl)methoxy]-4-phenoxy- (CA INDEX NAME)



IT 816454-68-9P, 4-Phenoxy-1,2-dihydro-3H-indazol-3-one
816454-70-3P, Ethyl 3-oxo-4-phenoxy-2,3-dihydro-1H-indazole-1-carboxylate 816454-73-6P, Ethyl 3-[(2-chlorobenzyl)oxy]-4-phenoxy-1H-indazole-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole and pyrazolopyridine derivs. useful as JNK inhibitors)

RN 816454-68-9 CAPLUS
CN 3H-Indazol-3-one, 1,2-dihydro-4-phenoxy- (CA INDEX NAME)



RN 816454-70-3 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 2,3-dihydro-3-oxo-4-phenoxy-, ethyl ester (CA INDEX NAME)



RN 816454-73-6 CAPLUS

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 1H-Indazole-1-carboxylic acid, 3-[(2-chlorophenyl)methoxy]-4-phenoxy-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1972:106429 CAPLUS
DOCUMENT NUMBER: 76:106429
ORIGINAL REFERENCE NO.: 76:17113a,17116a
TITLE: Light-sensitive color photographic film containing an indazolone derivative as purple coupler
INVENTOR(S): Boie, Immo; Schulte, Walter; Pelz, Willibald
PATENT ASSIGNEE(S): Agfa-Gevaert A.-G.
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2032171	A	19720113	DE 1970-2032171	19700630
BE 769116	A2	19711228	BE 1971-3192	19710628
GB 1335603	A	19731031	GB 1971-30340	19710629
FR 2100089	A5	19720317	FR 1971-24008	19710630
PRIORITY APPLN. INFO.:			DE 1970-2032171 A	19700630

AB Previously used indazolones yield, with color developer p-H2NC6H4NBu(CH2)4SO3H, dyes with undesirable absorption maximum >580 nm. Brilliant dyes with absorption maximum at 550-570 nm and stable to moist heat can be obtained with nondiffusing indazolones having a C8-20 alkoxy, aralkoxy, benzyloxy or benzyl substituent with C8-20 alkyl groups. Thus, 6-cetoxyindazolone is obtained from 2-nitro-4-hydroxybenzoic acid by etherification with C16H33Br, reduction of the NO2, diazotization and reduction to the o-hydrazinobenzoic acid, which undergoes ring closure when boiled in 2N KOH.

IT 36498-68-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36498-68-7 CAPLUS
CN 3H-Indazol-3-one, 4-[(4-hexadecylphenyl)methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 13:16:25 ON 12 DEC 2007)

     FILE 'REGISTRY' ENTERED AT 13:17:14 ON 12 DEC 2007
L1               STRUCTURE UPLOADED
L2             0 S L1
L3            17 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 13:17:40 ON 12 DEC 2007
L4             5 S L3 FULL

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                27.29     199.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -3.90      -3.90

STN INTERNATIONAL LOGOFF AT 13:18:51 ON 12 DEC 2007
```

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1277	(514/303,514/415,546/119,548/361.1).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/12/12 14:01
L2	0	("l1andnitrogenous").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/12/12 14:01
L3	7	l1 and nitrogenous	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/12/12 14:01